RESUMO
Fungal infections of the paranasal cavity are among the most widely spread illnesses nowadays. The aim of the current study was to estimate the effectiveness of an in situ gel loaded with voriconazoleâclove oil nano-transferosomes (VRC-CO-NT) in enhancing the activity of voriconazole against Aspergillus flavus, which causes rhinosinusitis. The nephrotoxic side effects of voriconazole may be reduced through the incorporation of the clove oil, which has antioxidant activity that protects tissue. The BoxâBehnken design was applied to formulate the VRC-CO-NT. The particle size, entrapment efficiency, antifungal inhibition zone, and serum creatinine concentration were considered dependent variables, and the soybean lecithin, VRC, and CO concentrations were considered independent ones. The final optimized formulation was loaded into a deacetylated gellan gum base and evaluated for its gelation, rheological properties, drug release profile, permeation capabilities, and in vivo nephrotoxicity. The optimum formulation was determined to be composed of 50 mg/mL lecithin, 18 mg/mL VRC, and 75 mg/mL CO, with a minimum particle size of 102.96 nm, an entrapment efficiency of 71.70%, an inhibition zone of 21.76 mm, and a serum creatinine level of 0.119 mmol/L. The optimized loaded in situ gel released 82.5% VRC after 12 hours and resulted in a 5.4-fold increase in drug permeation. The in vivo results obtained using rabbits resulted in a nonsignificant differentiation among the renal function parameters compared with the negative control group. In conclusion, nasal in situ gel loaded with VRC-CO-NT is considered an efficient novel carrier with enhanced antifungal properties with no signs of nephrotoxicity.
Assuntos
Antifúngicos/farmacologia , Aspergillus flavus/efeitos dos fármacos , Óleo de Cravo/farmacologia , Nanopartículas/química , Voriconazol/farmacologia , Animais , Antifúngicos/administração & dosagem , Antifúngicos/efeitos adversos , Antifúngicos/farmacocinética , Proteínas da Membrana Bacteriana Externa , Biomarcadores , Química Farmacêutica , Óleo de Cravo/administração & dosagem , Creatinina/sangue , Relação Dose-Resposta a Droga , Portadores de Fármacos/química , Liberação Controlada de Fármacos , Géis/química , Nefropatias/induzido quimicamente , Lipossomos/química , Seios Paranasais/metabolismo , Tamanho da Partícula , Coelhos , Reologia , Voriconazol/administração & dosagem , Voriconazol/efeitos adversos , Voriconazol/farmacocinéticaRESUMO
Limited data are available on antimicrobials exposure and microbiology evolution in pediatric acute myeloid leukemia (AML) patients underwent antimicrobials prophylaxis. To assess the effectiveness of antimicrobials prophylaxis, antibiotic susceptibilities of bacteria, and exposure of antimicrobials during intensive chemotherapy for AML patients, 90 consecutive de novo AML patients aged 0-18 years between January 1, 1997 and March 31, 2018 were enrolled. Vancomycin, ciprofloxacin and voriconazole prophylaxis was administered from January 1, 2010. During the preprophylaxis period, January 1997 to December 2009, 62 patients experienced a total of 87 episodes of bloodstream infection (BSI) and 17 episodes of invasive fungal infection (IFI) among 502 courses of chemotherapy. In contrast, 16 episodes of BSI occurred and no IFIs were reported to occur in 28 patients who received 247 courses of chemotherapy in the prophylaxis period. Patients who received antimicrobial prophylaxis had a significant reduction of BSI, IFI, and febrile neutropenia in comparison with patients without prophylaxis. Exposure to amikacin, carbapenem, amphotericin B was reduced in the prophylaxis period. Imipenem susceptibility of Enterobacter cloacae as well as vancomycin susceptibility of Enterococcus species were reduced in the prophylaxis period. At the time of the last follow up, patients with prophylaxis had a better subsequent 5-year overall survival rate than those without prophylaxis. Prophylactic antimicrobials administration in children with AML who undergo chemotherapy can significantly reduce the rates of life-threatening infection, exposure to antimicrobials, and might result in a better outcome.
Assuntos
Antibacterianos/uso terapêutico , Antibioticoprofilaxia/métodos , Antifúngicos/uso terapêutico , Bacteriemia/prevenção & controle , Neutropenia Febril/prevenção & controle , Leucemia Mieloide Aguda/microbiologia , Micoses/prevenção & controle , Antibacterianos/administração & dosagem , Antifúngicos/administração & dosagem , Bacteriemia/tratamento farmacológico , Criança , Ciprofloxacina/administração & dosagem , Ciprofloxacina/uso terapêutico , Neutropenia Febril/tratamento farmacológico , Feminino , Humanos , Imipenem/administração & dosagem , Imipenem/uso terapêutico , Leucemia Mieloide Aguda/complicações , Masculino , Micoses/tratamento farmacológico , Vancomicina/administração & dosagem , Vancomicina/uso terapêutico , Voriconazol/administração & dosagem , Voriconazol/uso terapêuticoRESUMO
The co-administration of voriconazole (VCZ) and Wuzhi tablet (WZ) is frequently prescribed for solid organ transplantation patients in China. However, the pharmacokinetic interactions between VCZ and WZ as well as its bioactive constituents, such as schisandrin A and schisandrol B, remain unknown. Therefore, the effects of WZ and the two lignans on the metabolism of VCZ and the potential role of cytochromeP450 (CYP450), especially cytochrome P450 2C19 (CYP2C19), were investigated. The results showed that WZ extensively inhibited the activities of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4. Noteworthy, 2.5 mg/mL WZ almost completely inhibited the activity of 2C19, and the inhibition ratio reached 78.6±3% and 63.5±4.6% for schisandrin A and schisandrol B at concentrations 100 µM, respectively. In addition, rats were treated with a single or consecutive 14 day oral dose of WZ (250 mg/kg), schisandrol B (10 mg/kg) and schisandrin A (10 mg/ kg). In rats treated with WZ, the AUC0-∞ value for intravenous VCZ dosing was increased by 80.2% (single dose, p < 0.05) and 66.4% (dosage for 14 day, p < 0.05) and the Cmax was increased by 10.5% (p < 0.05) and (20.6%, p < 0.05), respectively, much greater than that when VCZ (28 mg/kg) was given alone. Unexpectedly, the AUC and Cmax values after schisandrol B and schisandrin A treatment were significantly increased. However, the mRNA expression of liver CYP2C19 and the protein expression of liver CYP2C19 were surprisingly increased after treatment with WZ, schisandrol B and schisandrin A in rats. Therefore, attention should be paid to when WZ and VCZ are administered concomitantly, as dosage adjustment might become necessary. Further clinical study is warranted to validate the interaction between WZ and VCZ.
Assuntos
Citocromo P-450 CYP2C19/genética , Medicamentos de Ervas Chinesas/farmacologia , Interações Ervas-Drogas , Voriconazol/farmacocinética , Animais , Antifúngicos/administração & dosagem , Antifúngicos/farmacocinética , Área Sob a Curva , Ciclo-Octanos/isolamento & purificação , Ciclo-Octanos/farmacologia , Sistema Enzimático do Citocromo P-450/metabolismo , Dioxóis/isolamento & purificação , Dioxóis/farmacologia , Medicamentos de Ervas Chinesas/administração & dosagem , Humanos , Lignanas/isolamento & purificação , Lignanas/farmacologia , Fígado/metabolismo , Masculino , Compostos Policíclicos/isolamento & purificação , Compostos Policíclicos/farmacologia , Ratos , Ratos Sprague-Dawley , Comprimidos , Voriconazol/administração & dosagemRESUMO
OBJECTIVE: To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. ANIMALS STUDIED: Five healthy Thoroughbred horses. PROCEDURES: Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography-electrospray tandem-mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle. RESULTS: The mean maximum voriconazole concentrations in plasma and TF were 3.3 µg/mL at 1.5 h and 1.9 µg/mL at 1.6 h, respectively. Mean half-life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0-24 at steady state in TF (51.3 µgâh/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was >100 and 25.7, respectively. CONCLUSIONS: This study demonstrated the detailed single-dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK-PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK-PD analyses against pathogenic fungi in TF can be used to provide evidence-based medicine for equine keratomycosis.
Assuntos
Antifúngicos/uso terapêutico , Infecções Oculares Fúngicas/veterinária , Doenças dos Cavalos/tratamento farmacológico , Voriconazol/uso terapêutico , Administração Oral , Animais , Antifúngicos/administração & dosagem , Antifúngicos/farmacocinética , Antifúngicos/farmacologia , Área Sob a Curva , Aspergillus/efeitos dos fármacos , Infecções Oculares Fúngicas/tratamento farmacológico , Feminino , Doenças dos Cavalos/sangue , Cavalos/metabolismo , Masculino , Testes de Sensibilidade Microbiana , Lágrimas/metabolismo , Voriconazol/administração & dosagem , Voriconazol/farmacocinética , Voriconazol/farmacologiaRESUMO
OBJECTIVES: Voriconazole, amphotericin B (AmB) formulations, and isavuconazole are all included in guideline recommendations for treatment of patients with invasive aspergillosis (IA) but the relative efficacy of isavuconazole versus AmB formulations has not been directly compared. We aimed to estimate the relative efficacy of isavuconazole compared with AmB deoxycholate (AmB-D), liposomal AmB (L-AmB), and voriconazole for the treatment of patients with proven/probable IA. METHODS: Nine literature databases were screened for randomized controlled trials comparing treatments with any of voriconazole, AmB-D, L-AmB and isavuconazole for treatment of proven/probable IA. Articles meeting the criteria were included in a meta-analysis to determine the efficacy of AmB-D, L-AmB and voriconazole relative to isavuconazole based on all-cause mortality (ACM) and overall response using a fixed-effects model. RESULTS: Four articles were identified that compared L-AmB with AmB-D (Study 1), standard-dose L-AmB (3-5 mg/kg/day) with high-dose L-AmB (10 mg/kg/day; Study 2), voriconazole with AmB-D (Study 3), and isavuconazole with voriconazole (Study 4). In the network meta-analysis, isavuconazole was statistically superior to AmB-D on both ACM (odds ratio [95% credible intervals] shown as natural log, 1.00 [0.26, 1.74]) and overall response (-1.39 [-2.21, -0.63]). Differences between isavuconazole, and standard-dose L-AmB, high-dose L-AmB and voriconazole were not statistically significant for either ACM (0.18 [-1.17, 1.53], 0.50 [-1.11, 2.13] and 0.32 [-0.19, 0.84], respectively) or overall response (-0.99 [-2.21, 0.29], -0.89 [-2.41, 0.65] and 0.06 [-0.43, 0.57], respectively). CONCLUSIONS: This data suggests that the efficacy of isavuconazole for treatment of IA is superior to AmB-D and comparable with both L-AmB and voriconazole.
Assuntos
Antifúngicos/uso terapêutico , Aspergilose/tratamento farmacológico , Nitrilas/administração & dosagem , Piridinas/administração & dosagem , Triazóis/administração & dosagem , Anfotericina B/administração & dosagem , Ácido Desoxicólico/administração & dosagem , Combinação de Medicamentos , Humanos , Metanálise em Rede , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Voriconazol/administração & dosagemRESUMO
Therapeutic concentrations of voriconazole in invasive fungal infections (IFIs) are ensured using a drug monitoring approach, which relies on attainment of steady-state pharmacokinetics. For voriconazole, time to reach steady state can vary from 5-7 days, not optimal for critically ill patients. We developed a population pharmacokinetic/pharmacodynamic model-based approach to predict doses that can maximize the net benefit (probability of efficacy-probability of adverse events) and ensure therapeutic concentrations, early on during treatment. The label-recommended 200 mg voriconazole dose resulted in attainment of targeted concentrations in ≥80% patients in the case of Candida spp. infections, as compared to only 40-50% patients, with net benefit ranging from 5.8-61.8%, in the case of Aspergillus spp. infections. Voriconazole doses of 300-600 mg were found to maximize the net benefit up to 51-66.7%, depending on the clinical phenotype (due to CYP2C19 status and pantoprazole use) of the patient and type of Aspergillus infection.
Assuntos
Antifúngicos/administração & dosagem , Aspergilose/tratamento farmacológico , Candidíase/tratamento farmacológico , Cálculos da Dosagem de Medicamento , Infecções Fúngicas Invasivas/tratamento farmacológico , Modelos Biológicos , Voriconazol/administração & dosagem , Adulto , Idoso , Antifúngicos/efeitos adversos , Antifúngicos/sangue , Antifúngicos/farmacocinética , Aspergilose/sangue , Aspergilose/diagnóstico , Aspergilose/microbiologia , Aspergillus/classificação , Aspergillus/efeitos dos fármacos , Candida/classificação , Candida/efeitos dos fármacos , Candidíase/sangue , Candidíase/diagnóstico , Candidíase/microbiologia , Citocromo P-450 CYP2C19/genética , Citocromo P-450 CYP2C19/metabolismo , Interações Medicamentosas , Monitoramento de Medicamentos , Feminino , Genótipo , Humanos , Infecções Fúngicas Invasivas/sangue , Infecções Fúngicas Invasivas/diagnóstico , Infecções Fúngicas Invasivas/microbiologia , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Pantoprazol/efeitos adversos , Variantes Farmacogenômicos , Fenótipo , Inibidores da Bomba de Prótons/efeitos adversos , Medição de Risco , Voriconazol/efeitos adversos , Voriconazol/sangue , Voriconazol/farmacocinéticaRESUMO
We report the recent isolation of Cryptococcus laurentii from the feces of a patient with Hodgkin's lymphoma who underwent autologous hematopoietic stem cell transplant (HSCT). The organism was identified using microscopic morphology, cultural characteristics, and biochemical tests including sugar assimilation. Minimum inhibitory concentration of various antifungals was determined by microbroth dilution method. The recovery of pure culture of C. laurentii from stool culture, and the patient's response to treatment with voriconazole support its potential etiological role. To the best of our knowledge, we report the first case of diarrhea caused by C. laurentii in an HSCT recipient.
Assuntos
Antifúngicos/uso terapêutico , Criptococose/microbiologia , Cryptococcus/isolamento & purificação , Diarreia/microbiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Doença de Hodgkin/cirurgia , Voriconazol/uso terapêutico , Administração Intravenosa , Administração Oral , Adulto , Antibioticoprofilaxia , Antifúngicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Proteína C-Reativa/análise , Carmustina/efeitos adversos , Carmustina/uso terapêutico , Criptococose/sangue , Criptococose/tratamento farmacológico , Citarabina/efeitos adversos , Citarabina/uso terapêutico , Diarreia/sangue , Diarreia/tratamento farmacológico , Etoposídeo/efeitos adversos , Etoposídeo/uso terapêutico , Fezes/microbiologia , Fluconazol/uso terapêutico , Humanos , Melfalan/efeitos adversos , Melfalan/uso terapêutico , Testes de Sensibilidade Microbiana , Condicionamento Pré-Transplante/efeitos adversos , Condicionamento Pré-Transplante/métodos , Transplante Autólogo/efeitos adversos , Voriconazol/administração & dosagemRESUMO
Background: Scedosporiosis is associated with a mortality rate of up to 90% in patients suffering from disseminated infections. Recommended first-line treatment is voriconazole, but epidemiological cut-off values and clinical breakpoints have not been determined. Objectives: To correlate voriconazole treatment response in mice suffering from disseminated scedosporiosis with MIC values determined using CLSI broth microdilution, Etest (bioMérieux) and disc diffusion. Methods: Voriconazole MICs for 31 Scedosporium apiospermum strains were determined using CLSI broth microdilution, Etest and disc diffusion. Groups of mice were challenged intravenously with 1 out of 16 S. apiospermum strains (voriconazole CLSI broth microdilution MIC range: 0.125-8.0 mg/L) and treated with 40 mg/kg voriconazole orally by gavage once daily. Efficacy of voriconazole was evaluated by a statistically significant ( P < 0.05) reduction in fungal burden in brain. Results: A categorical agreement of 90.4% was reached for CLSI broth microdilution and disc diffusion and of 93.6% for CLSI broth microdilution and Etest. Correlation of CLSI MICs and in vivo outcome was good, as mice challenged with strains with an MIC ≤2 mg/L responded to voriconazole therapy in 92.3% and those challenged with strains with an MIC ≥4 mg/L responded to voriconazole therapy in 33.3%. Conclusions: CLSI broth microdilution and Etest deliver comparable results that enable a prediction of in vivo outcome. Our results suggest that voriconazole is able to reduce fungal burden in the brain of 92.3% of all mice challenged with strains with voriconazole CLSI MICs ≤2 mg/L, while mice challenged with strains with CLSI MICs ≥4 mg/L showed limited response to voriconazole treatment.
Assuntos
Antifúngicos/farmacologia , Antifúngicos/uso terapêutico , Micoses/tratamento farmacológico , Scedosporium/efeitos dos fármacos , Voriconazol/farmacologia , Voriconazol/uso terapêutico , Animais , Antifúngicos/administração & dosagem , Encéfalo/efeitos dos fármacos , Encéfalo/microbiologia , Humanos , Camundongos , Testes de Sensibilidade Microbiana , Micoses/sangue , Micoses/microbiologia , Valor Preditivo dos Testes , Voriconazol/administração & dosagemRESUMO
INTRODUCTION: Voriconazole is a broad-spectrum antifungal agent commonly used to treat invasive fungal infections (IFI), including aspergillosis, candidiasis, Scedosporium infection, and Fusarium infection. IFI often occur in immunocompromised patients, leading to increased morbidity and mortality. AREAS COVERED: The objective of this review is to summarize the pharmacodynamic properties of voriconazole and to provide considerations for potential optimal dosing strategies. Studies have demonstrated superior clinical response when an AUC/MIC >25 or Cmin/MIC >1 is attained in adult patients, correlating to a trough concentration range as narrow as 2-4.5 mg/L; however, these targets are poorly established in the pediatric population. Topics in this discussion include voriconazole use in multiple age groups, predisposing patient factors for IFI, and considerations for clinicians managing IFI. Expert commentary: The relationship between voriconazole dosing and exposure is not well defined due to the large inter- and intra-subject variability. Development of comprehensive decision support tools for individualizing dosing, particularly in children who require higher dosing, will help to increase the probability of achieving therapeutic efficacy and decrease sub-therapeutic dosing and adverse events.
Assuntos
Antifúngicos/uso terapêutico , Infecções Fúngicas Invasivas/tratamento farmacológico , Voriconazol/uso terapêutico , Antifúngicos/administração & dosagem , Antifúngicos/farmacocinética , Antifúngicos/farmacologia , Área Sob a Curva , Relação Dose-Resposta a Droga , Predisposição Genética para Doença , Humanos , Infecções Fúngicas Invasivas/genética , Infecções Fúngicas Invasivas/imunologia , Infecções Fúngicas Invasivas/microbiologia , Testes de Sensibilidade Microbiana , Modelos Biológicos , Voriconazol/administração & dosagem , Voriconazol/farmacocinética , Voriconazol/farmacologiaRESUMO
Voriconazole is the agent of choice for the treatment of invasive aspergillosis in children at least 2 years of age. The galactomannan index is a routinely used diagnostic marker for invasive aspergillosis and can be useful for following the clinical response to antifungal treatment. The aim of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) mathematical model that links the pharmacokinetics of voriconazole with the galactomannan readout in children. Twelve children receiving voriconazole for treatment of proven, probable, and possible invasive fungal infections were studied. A previously published population PK model was used as the Bayesian prior. The PK-PD model was used to estimate the average area under the concentration-time curve (AUC) in each patient and the resultant galactomannan-time profile. The relationship between the ratio of the AUC to the concentration of voriconazole that induced half maximal killing (AUC/EC50) and the terminal galactomannan level was determined. The voriconazole concentration-time and galactomannan-time profiles were both highly variable. Despite this variability, the fit of the PK-PD model was good, enabling both the pharmacokinetics and pharmacodynamics to be described in individual children. (AUC/EC50)/15.4 predicted terminal galactomannan (P= 0.003), and a ratio of >6 suggested a lower terminal galactomannan level (P= 0.07). The construction of linked PK-PD models is the first step in developing control software that enables not only individualized voriconazole dosages but also individualized concentration targets to achieve suppression of galactomannan levels in a timely and optimally precise manner. Controlling galactomannan levels is a first critical step to maximizing clinical response and survival.
Assuntos
Antifúngicos/farmacocinética , Aspergilose/tratamento farmacológico , Aspergillus fumigatus/efeitos dos fármacos , Polissacarídeos Fúngicos/análise , Mananas/análise , Voriconazol/farmacocinética , Antifúngicos/administração & dosagem , Antifúngicos/sangue , Área Sob a Curva , Aspergilose/sangue , Aspergilose/microbiologia , Aspergillus fumigatus/crescimento & desenvolvimento , Aspergillus fumigatus/metabolismo , Biomarcadores/análise , Criança , Pré-Escolar , Simulação por Computador , Monitoramento de Medicamentos , Feminino , Galactose/análogos & derivados , Humanos , Masculino , Testes de Sensibilidade Microbiana , Modelos Estatísticos , Medicina de Precisão , Voriconazol/administração & dosagem , Voriconazol/sangueRESUMO
In this study, we investigated the in vitro antifungal effects of itraconazole/voriconazole (ITR/VRC) alone and in combination with tetrandrine (TET) against 23 clinical isolates of A. fumigatus using a chequerboard microdilution method. The dynamic antifungal effects of TET with ITR/VRC against A. fumigatus were assessed in vivo using time-kill curves following systemic infection of mice with A. fumigatus. After treatment, efflux pump activity was determined by the efflux of rhodamine 6G (R6G). When ITR was combined with TET, ITR MICs were reduced from 0.125-32 to 0.0625-2 µg ml(-1), and TET MICs were reduced from 256-512 to 8-64 µg ml(-1). When VRC was combined with TET, VRC MICs were reduced from 0.125-2 to 0.03125-0.5 µg ml(-1), and TET MICs were reduced from 256-512 to 8-256 µg ml(-1). Time-kill curves revealed that A. fumigatus viability was reduced after treatment with ITR/VRC combined with TET versus ITR/VRC alone. ITR/VRC combined with TET significantly prolonged mouse survival and reduced kidney and brain tissue burdens versus ITR/VRC alone (P < 0.05). Moreover, TET inhibited R6G efflux of A. fumigatus. Thus, in vitro and in vivo, TET acted synergistically with ITR/VRC against A. fumigatus, and the synergistic mechanism was related to inhibition of the drug efflux pump.
Assuntos
Aspergilose/tratamento farmacológico , Aspergillus fumigatus/efeitos dos fármacos , Benzilisoquinolinas/uso terapêutico , Itraconazol/uso terapêutico , Voriconazol/uso terapêutico , Animais , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Aspergilose/microbiologia , Benzilisoquinolinas/administração & dosagem , Ciclofosfamida/toxicidade , Quimioterapia Combinada , Hospedeiro Imunocomprometido , Imunossupressores/toxicidade , Itraconazol/administração & dosagem , Camundongos , Testes de Sensibilidade Microbiana , Voriconazol/administração & dosagemRESUMO
Majocchi's granuloma (MG) is a rare deep skin dermatophyte infection that can occur either in immunocompetent or in immunocompromised individuals. Oral itraconazole or terbinafine is considered to be the first choice of treatment. We report an immunocompetent man with deep nodular form of MG, the form which is generally found in immunosuppressed individuals. Previous treatment with either oral itraconazole or terbinafine yielded no apparent improvement. After a series of examination, the man was diagnosed as having Trichophyton rubrum-induced MG mixed with bacterial infection as evidenced by growth of Klebsiella pneumoniae in tissue bacterial culture. The patient was treated with a combination of cefoselis and levofloxacin for bacterial clearance followed by voriconazole treatment. After approximately 4 months of voriconazole treatment, the lesions completely resolved. Alternative medicine (voriconazole) can be considered in case of refractory infections during MG treatment.
Assuntos
Antifúngicos/administração & dosagem , Coinfecção/tratamento farmacológico , Granuloma/tratamento farmacológico , Tinha/tratamento farmacológico , Trichophyton/isolamento & purificação , Voriconazol/administração & dosagem , Antibacterianos/administração & dosagem , Ceftizoxima/administração & dosagem , Ceftizoxima/análogos & derivados , Coinfecção/complicações , Coinfecção/patologia , Granuloma/microbiologia , Granuloma/patologia , Humanos , Infecções por Klebsiella/complicações , Infecções por Klebsiella/tratamento farmacológico , Infecções por Klebsiella/patologia , Klebsiella pneumoniae/isolamento & purificação , Levofloxacino/administração & dosagem , Masculino , Pessoa de Meia-Idade , Tinha/complicações , Tinha/patologia , Resultado do TratamentoRESUMO
Although amphotericin B-azole combination therapy has traditionally been questioned due to potential antagonistic interactions, it is often used successfully to treat refractory invasive aspergillosis. So far, pharmacodynamic (PD) interactions have been assessed with conventional in vitro tests, which do not mimic human serum concentrations and animal models using limited doses. We therefore simulated the human serum concentration profiles of amphotericin B and voriconazole in an in vitro dialysis/diffusion closed pharmacokinetic-pharmacodynamic (PK-PD) model and studied the pharmacodynamic interactions against an azole-resistant and an azole-susceptible Aspergillus fumigatus isolate, using Bliss independence and canonical mixture response surface analyses. Amphotericin B dosing regimens with the drug administered every 24 h (q24h) were combined with voriconazole q12h dosing regimens. In vitro PK-PD combination data were then combined with human PK data by using Monte Carlo analysis. The target attainment rate and the serum concentration/MIC ratio were calculated for isolates with different MICs. Synergy (20 to 31%) was observed at low amphotericin B-high voriconazole exposures, whereas antagonism (-6 to -16%) was found at high amphotericin B-low voriconazole exposures for both isolates. Combination therapy resulted in 17 to 48% higher target attainment rates than those of monotherapy regimens for isolates with voriconazole/amphotericin B MICs of 1 to 4 mg/liter. Optimal activity was found for combination regimens with a 1.1 total minimum concentration of drug in serum (tCmin)/MIC ratio for voriconazole and a 0.5 total maximum concentration of drug in serum (tCmax)/MIC ratio for amphotericin B, whereas the equally effective monotherapy regimens required a voriconazole tCmin/MIC ratio of 1.8 and an amphotericin B tCmax/MIC ratio of 2.8. Amphotericin B-voriconazole combination regimens were more effective than monotherapy regimens. Therapeutic drug monitoring can be employed to optimize antifungal combination therapy with low-dose (≤0.6 mg/kg) amphotericin B-based combination regimens against resistant isolates for minimal toxicity.
Assuntos
Antifúngicos/uso terapêutico , Aspergilose/tratamento farmacológico , Azóis/uso terapêutico , Polienos/uso terapêutico , Anfotericina B/administração & dosagem , Anfotericina B/uso terapêutico , Antifúngicos/farmacocinética , Azóis/farmacocinética , Interações Medicamentosas , Monitoramento de Medicamentos , Farmacorresistência Fúngica , Quimioterapia Combinada , Meia-Vida , Humanos , Testes de Sensibilidade Microbiana , Modelos Estatísticos , Método de Monte Carlo , Polienos/farmacocinética , Voriconazol/administração & dosagem , Voriconazol/uso terapêuticoRESUMO
Cerebral aspergillosis is a rare and highly fatal infection that mainly affects immunocompromised patients. We report on a case of a heart transplanted Caucasian man, who arrived at our hospital because of the onset of diplopy. We performed a broad diagnostic work-up: the brain MRI showed a single ring-enhancing thalamo-mesencephalic area suggestive of abscess lesion; cerebrospinal fluid (CSF) analysis disclosed galactomannan and beta-D-glucan antigens. Thus the antifungal therapy was immediately started. We decided to discontinue the therapy 16 months later because of severe hepatic toxicity, given that the patient was persistently asymptomatic, brain imaging showed a progressive resolution of the abscess area and CSF antigen analysis was persistently negative. The follow-up at three months was unchanged.
Assuntos
Anfotericina B/administração & dosagem , Antifúngicos/administração & dosagem , Aspergilose/complicações , Aspergillus/isolamento & purificação , Abscesso Encefálico/microbiologia , Transplante de Coração , Hospedeiro Imunocomprometido , Voriconazol/administração & dosagem , Administração Intravenosa , Idoso , Aspergilose/diagnóstico , Aspergilose/tratamento farmacológico , Abscesso Encefálico/diagnóstico , Abscesso Encefálico/tratamento farmacológico , Quimioterapia Combinada , Humanos , Masculino , Mesencéfalo/microbiologia , Mesencéfalo/patologia , Tálamo/microbiologia , Tálamo/patologia , Fatores de Tempo , Resultado do TratamentoRESUMO
OBJECTIVE: The objective of this study was to evaluate the efficacy of combinations of nystatin-intralipid, found previously to be more active than nystatin, with antifungals of different mode of activity, against Aspergillus terreus. METHODS: Antifungal activity of combinations of nystatin-intralipid with voriconazole, caspofungin, terbinafine or 5-fluorocytosine were evaluated by the checkerboard and disk diffusion methods. The results were compared to those obtained with nystatin. RESULTS: The combination of nystatin-intralipid with caspofungin exhibited better antifungal activity than each drug alone and resulted in a synergistic interaction in three out of six tested strains of A. terreus. No such effect was obtained with Nystatin and caspofungin. Nystatin-intralipid or nystatin with voriconazole yielded indifferent interactions. When nystatin-intralipid was combined with terbinafine, a strong antagonism was produced in all six A. terreus strains. This effect was observed both by checkerboard and disk diffusion methods. In contrast no interaction or only slight antagonism was observed in the combination of nystatin with terbinafine. Disk diffusion method revealed similar inhibition zones when disks impregnated with 5-fluorocytosine were placed on plain, nystatin-intralipid or nystatin containing agar plates. CONCLUSIONS: Among four tested combinations, only combination of nytatin-intralipid with caspofungin, a representative of the echinocandin class of antifungals, resulted in synergistic interaction. Antagonism obtained by combining nystatin-intralipid with terbinafine can be explained by existence of hydrophobic interaction between these two compounds interfering with their antifungal action. The fact that nystatin-intralipid and nystatin interact differently with other antifungals, may indicate differences in their mechanisms of activity.
Assuntos
Antifúngicos/farmacologia , Aspergillus/efeitos dos fármacos , Nistatina/farmacologia , Fosfolipídeos/farmacologia , Óleo de Soja/farmacologia , Antifúngicos/administração & dosagem , Aspergillus/crescimento & desenvolvimento , Caspofungina , Combinação de Medicamentos , Equinocandinas/administração & dosagem , Equinocandinas/farmacologia , Emulsões/administração & dosagem , Emulsões/farmacologia , Flucitosina/administração & dosagem , Flucitosina/farmacologia , Humanos , Lipopeptídeos , Testes de Sensibilidade Microbiana/métodos , Naftalenos/administração & dosagem , Naftalenos/farmacologia , Nistatina/administração & dosagem , Fosfolipídeos/administração & dosagem , Óleo de Soja/administração & dosagem , Terbinafina , Voriconazol/administração & dosagem , Voriconazol/farmacologiaRESUMO
Azole resistance is an emerging problem in Aspergillus fumigatus and is associated with a high probability of treatment failure. An azole resistance mechanism typically decreases the activity of multiple azole compounds, depending on the mutation. As alternative treatment options are limited and in some isolates the minimum inhibitory concentration (MIC) increases by only a few two-fold dilutions steps, we investigated if voriconazole and posaconazole have a role in treating azole-resistant Aspergillus disease. The relation between resistance genotype and phenotype, pharmacokinetic and pharmacodynamic properties, and (pre)clinical treatment efficacy were reviewed. The results were used to estimate the exposure needed to achieve the pharmacodynamic target for each MIC. For posaconazole adequate exposure can be achieved only for wild type isolates as dose escalation does not allow PD target attainment. However, the new intravenous formulation might result in sufficient exposure to treat isolates with a MIC of 0.5 mg/L. For voriconazole our analysis indicated that the exposure needed to treat infection due to isolates with a MIC of 2 mg/L is feasible and maybe isolates with a MIC of 4 mg/L. However, extreme caution and strict monitoring of drug levels would be required, as the probability of toxicity will also increase.
Assuntos
Antifúngicos/uso terapêutico , Aspergilose/tratamento farmacológico , Aspergillus fumigatus/efeitos dos fármacos , Farmacorresistência Fúngica Múltipla , Modelos Biológicos , Triazóis/uso terapêutico , Voriconazol/uso terapêutico , Animais , Antifúngicos/administração & dosagem , Antifúngicos/efeitos adversos , Antifúngicos/farmacocinética , Aspergilose/sangue , Aspergilose/microbiologia , Aspergillus fumigatus/genética , Aspergillus fumigatus/metabolismo , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Quimioterapia Combinada/efeitos adversos , Humanos , Testes de Sensibilidade Microbiana , Mutação , Pesquisa Translacional Biomédica/tendências , Triazóis/administração & dosagem , Triazóis/efeitos adversos , Triazóis/farmacocinética , Voriconazol/administração & dosagem , Voriconazol/efeitos adversos , Voriconazol/farmacocinéticaRESUMO
AIMS: Echinocandins are recommended for the treatment of candidaemia in moderately severe to severely ill patients. Step-down or de-escalation from echinocandin to fluconazole is advised in patients who are clinically stable but data in relation to step-down therapy are sparse. Using our hospital intravenous to oral switch therapy (IVOST) policy to guide antifungal de-escalation in patients with candidaemia, we aimed to determine what proportion of patients are de-escalated to fluconazole, the timescale to step-down, associated reduction in consumption of echinocandins and antifungal cost savings. METHODOLOGY: Patients with candidaemia were followed from April 2011 to March 2013. RESULTS: A total of 37 episodes of candidaemia were documented during the study period. Twenty-seven patients were commenced on an echinocandin or voriconazole and 19 (70.3%) were de-escalated to fluconazole based on the IVOST policy. The mean and median number of days to de-escalation of therapy was 4.6 and 5 days, respectively. One patient whose therapy was de-escalated relapsed. The overall 30 day crude mortality was 37.1%. The step-down approach led to significant saving in antifungal drug cost of £1133.88 per candidaemic episode and £2208.08 per de-escalation. CONCLUSION: Implementation of IVOST policy led to streamlining of antifungal therapy.